Table 3 Characteristics of patients in the AKI group and the non-AKI group
Parameters | AKI group ( n = 15) | Non-AKI group ( n = 251) | p-value |
|---|---|---|---|
PIPC/TAZ, n (%) | 14 (93.3) | 149 (59.4) | 0.011 |
Age, median (range) | 80 (59 – 96) | 75 (21 – 95) | 0.31 |
Female, n (%) | 6 (40.0) | 79 (31.5) | 0.57 |
Hypertension, n (%) | 8 (53.3) | 122 (48.6) | 0.79 |
Heart failure, n (%) | 5 (33.3) | 34 (13.5) | 0.051 |
Diabetes, n (%) | 9 (60.0) | 59 (23.5) | 0.006 |
Malignancy, n (%) | 7 (46.7) | 86 (34.3) | 0.40 |
Prostatic hypertrophy, n (%) | 4 (26.7) | 45 (17.9) | 0.49 |
CKD, n (%) | 12 (80.0) | 95 (37.8) | 0.0019 |
Contrast media, n (%) | 2 (13.3) | 27 (10.8) | 0.67 |
NSAIDs, n (%) | 5 (33.3) | 124 (49.4) | 0.29 |
ACE-I / ARB, n (%) | 6 (40.0) | 73 (29.1) | 0.39 |
Diuretics, n (%) | 7 (46.7) | 59 (23.5) | 0.062 |
Calcineurin inhibitors, n (%) | 0 (0) | 2 (0.8) | 1 |
Catecholamine, n (%) | 2 (13.3) | 8 (3.2) | 0.10 |
Aminoglycoside, n (%) | 0 (0) | 2 (0.8) | 1 |
Acyclovir, n (%) | 0 (0) | 1 (0.4) | 1 |
Cisplatin, n (%) | 0 (0) | 1 (0.4) | 1 |